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ABSTRACT
Tumor necrosis factor- (TNF) has been implicated in the reactivation of cytomegalovirus (CMV) at a cellular
level. We therefore hypothesized that increased posttransplantation TNF levels may be associated with the
development of CMV antigenemia (CMV-Ag). We studied 134 patients undergoing allogeneic hematopoietic
stem cell transplantation. After excluding CMV-negative donor and recipient pairs, 94 patients were evaluable.
By cluster analysis, 2 groups were designated by TNF levels obtained between days 4 and 7 after transplan-
tation: 58 patients had low levels (median, 0 pg/mL; range, 0-5.5 pg/mL), and 36 patients had high levels
(median, 43.75 pg/mL; range, 7.5-1756 pg/mL). To determine the independent effect of TNF on the devel-
opment of CMV-Ag and acute graft-versus-host disease and on survival, Kaplan-Meier and Cox models
stratified by TNF patient groups were evaluated. High TNF levels were associated with a more rapid onset of
CMV-Ag (P < .001) and with the occurrence of the composite end point of CMV-Ag or death (P < .001).
Factors independently associated with CMV-Ag in multivariate analysis were a high TNF level (hazard ratio
[HR], 2.57; P  .003) and acute graft-versus-host disease (as a time-dependent covariate; HR, 2.30; P  .010).
Factors independently associated with the composite end point of CNV-Ag or death were a high TNF level
(HR, 2.42; P < .001) and patient age (per year; HR, 1.93; P  .017). In conclusion, a high posttransplantation
TNF level is significantly associated with the risk for developing CMV infection. Early detection of high levels
of TNF may be used to identify patients at high risk for developing CMV-Ag.
© 2005 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT) is
n important therapeutic modality for malignant and
onmalignant disorders. Patients are immunocompro-
ised after transplantation because of conditioning, im-
unosuppressive drugs, or graft-versus-host disease
GVHD) [1]. A major complication of transplantation
mmunosuppression is cytomegalovirus (CMV) infec-
ion, which contributes signiﬁcantly to morbidity and
ortality after transplantation [2-4]. Several groups have
emonstrated that CMV disease may be reduced by
mproved surveillance and preemptive antiviral thera-
ies; however, CMV infection continues to be a major t
98oncern after transplantation [5-9]. The deleterious ef-
ects of CMV infection include indirect effects of CMV
eactivation that are due to immunosuppressive status
nduced by CMV; these lead to a risk of other infections
10]. In addition, drugs such as foscarnet and ganciclovir
o treat CMV reactivation have toxic effects, including
enal failure or neutropenia, that predispose to invasive
acterial or fungal infections [11,12].
Tumor necrosis factor- (TNF) has an important
ole in the pathogenesis of a variety of inﬂammatory
isorders [13]. Studies have indicated a role for TNF
n major transplant-related complications, including
eno-occlusive disease, pneumonitis, and severe endo-
helial leakage syndrome [14]. In HSCT, both murine
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TNF- and CMV Infection after Stem Cell Transplantation
Bodels and clinical studies suggest that TNF released
fter conditioning is involved in the pathogenesis of
cute GVHD (aGVHD) [14-19]. Furthermore, use of
ransplanted T cells from a TNF-deﬁcient donor ab-
ogates the development of idiopathic pneumonia syn-
rome, thus establishing the requirement for donor-
erived TNF in a murine model [20]. Collectively,
hese studies suggest that TNF is a signiﬁcant medi-
tor in the pathogenesis of posttransplantation com-
lications. However, the association between TNF
nd the subsequent development of CMV infection is
ot known.
After allogeneic stem cell transplantation (SCT),
atients are at risk for CMV infection because of a
ariety of factors, including donor and/or recipient
MV serologic status and immunosuppressive medi-
ations [21]. The occurrence of aGVHD with associ-
ted use of corticosteroids increases the risk of devel-
ping CMV infection [21]. Because TNF has been
hown to stimulate CMV reactivation at a cellular
evel in a dose-dependent manner [22,23], we hypoth-
sized that high TNF levels in the immediate post-
ransplantation period may be associated with subse-
uent development of CMV infection, independently
f GVHD. With the recent advent of anti-TNF ther-
pies [24-26], ﬁnding an association between TNF
nd CMV infection may be clinically relevant to iden-
ify patients at high risk for developing CMV infection
nd initiate a preemptive strategy of antiviral treat-
ent.
ATERIALS AND METHODS
atients
We prospectively collected blood samples and
linical data from 134 patients who underwent alloge-
eic HSCT. For the purpose of this study, we ex-
luded 32 CMV-negative donor and recipient (D/
) pairs (of which only 1 patient developed CMV-
g). An additional 8 patients were excluded because
hey had missing TNF levels in the ﬁrst week after
ransplantation. The demographics of the patients are
escribed in Table 1. Most patients (68%) received
eripheral blood stem cells, and the remainder (32%)
eceived bone marrow or cord blood transplants. Six-
y-three patients had transplants from related and 31
rom unrelated donors. Patients were treated with
yeloablative (65%) or nonmyeloablative (35%) con-
itioning regimens based on institutional protocols or
reatment plans. GVHD prophylaxis consisted of ta-
rolimus or cyclosporin A along with minidose meth-
trexate. Patients who developed aGVHD grades II to
V were treated with methylprednisolone 2 mg/kg
ith a scheduled taper of 25% every 4 days, depending
n response. If no response was noted, the dose was
eld and/or additional immunosuppressive agents t
B&MTuch as daclizumab, mycophenolate mofetil, and/or
nvestigational agents were indicated. The primary
tudy end point was the appearance of CMV antigen-
mia (CMV-Ag). Secondary study end points included
atient death, the composite end point of patient
eath or CMV-Ag, aGVHD (grades II-IV), and CMV
isease. Patients were followed up until death, the last
ollow-up date, or the study end point of June 18,
004. The median follow-up was 1103 days (range,
0-1792 days).
NF Measurements
Blood samples were collected twice during the
rst week after transplantation between 4 and 7 days.
lasma samples were stored frozen at 200°C until
nalysis. Plasma TNF levels were measured by en-
yme-linked immunosorbent assay according to stan-
ard protocols and reagents (Endogen, Woburn, MA).
ll cytokine assays were performed in duplicate or
riplicate (according to sample availability), and the
verage is reported in picograms per milliliter. On the
asis of the average of the sample results obtained
etween days 4 and 7, the patients were grouped into
ow- or high-TNF cluster groups, as described in the
tatistical methods.
MV Surveillance and Preemptive Therapy
CMV-Ag testing was performed through day
100 by using the pp65 antigenemia assay that detects
he said antigen by immunoﬂuorescence [11]. After
ay 100, CMV-Ag was monitored in patients consid-
red to be at high risk on the basis of active GVHD
nd in those taking immunosuppressive medications.
ositive CMV-Ag was treated with ganciclovir 5
g/kg intravenously twice daily for 2 weeks followed
y 5 mg/kg intravenously daily for 1 week. Alterna-
able 1. Patient Characteristics
Variable Data
94*
ecipient male 60.6%
onor male 55.3%
atient age, y (mean  SD) 46.5  12.3
onor age, y (mean  SD) 44.6  13.0
ecipient positive 77.7%
onor positive 68.1%
yeloablative conditioning 64.9%
elated donor transplant 67.0%
eripheral blood stem cell graft source 68.1%
urvival rate (within 150 and after
transplantation)†
Patient survival 61.5%
CMV-Ag 45.6%
Acute GVHD (within 100 d) 34.8%
Excluding CMV pretransplantation D/R pairs from 134 pa-
tients total.
Kaplan-Meier survival rate at 150 days after transplantation.ively, valganciclovir 900 mg orally twice daily for 2
699
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7eeks was used, followed by 900 mg daily for 1 week.
f antigenemia persisted after 4 weeks of treatment or
f it increased after 3 weeks, treatment was switched to
oscarnet.
linical Study End Points
The primary study end point was CMV infection,
eﬁned as positive CMV-Ag within the ﬁrst 150 days.
econdary end points were clinical CMV disease and
he composite outcome of CMV-Ag and death. Cri-
eria for CMV disease have been previously deﬁned as
neumonia, gastrointestinal disease, or end-organ lo-
alization [5,27]. Acute GVHD grade II to IV occur-
ing before day 100 after transplantation was deﬁned
ccording to consensus criteria [28]. Conditioning
egimens were deﬁned as ablative if high-dose therapy
as administered. High-dose therapy is that after
hich marrow recovery would not be expected with-
ut treatment. All other regimens with reduced inten-
ity were deﬁned as nonmyeloablative.
tatistical Methods
We classiﬁed TNF-level categories by using clus-
er analysis on the log-transformed counts {log [TNF
pg/mL)  1]}. We chose to divide the patients ac-
ording to high and low TNF levels. To designate the
utoff level for high versus low TNF levels, a univar-
ate disjoint clustering method based on euclidean
quared distances was used for the transformed vari-
bles. The clustering algorithm minimized the abso-
ute difference between the data and the correspond-
ng cluster medians. Similar statistical procedures
ere conducted for classifying the CD3 and CD34
ells infused. The 2 TNF categories were analyzed
ith univariate Kaplan-Meier models and Cox pro-
ortional hazard models, adjusted for relevant covari-
tes, to assess their association with outcomes of in-
erest. The log-rank test was used to test the
ssociation of TNF group levels and the time to the
pplicable outcome. Models were constructed for the
utcomes of CMV-Ag onset, patient death, composite
MV-Ag, patient death, and CMV disease onset. Sur-
ival models for CMV onset were truncated at 150
ays because there were no CMV-Ag events after this
oint and to maintain the proportionality of covariate
actors as in the Cox model assumptions. We used a
tepwise backward variable-elimination method simi-
ar to that of Wahlby et al. [29] to construct our
ultivariate model. The P value threshold of remain-
ng in the model was .15. Covariates entered into the
odels were sex match, patient age (treated as a con-
inuous variable), disease risk level (high or standard),
raft source (bone marrow or peripheral blood stem
ell), related or unrelated donor, number of CD34
ells infused, number of CD3 cells infused, donor (D)
nd recipient (R) pretransplantation CMV combina- T
00ion (D/R, D/R, and D/R), conditioning
ype, and days to onset of aGVHD as a time-depen-
ent covariate. We also examined the association of
MV-Ag and TNF levels in several strata that were
igniﬁcantly disproportionately represented in the 2
NF groups. To further ascertain the viability of the
roup delineation by the cluster technique, we pro-
uced a receiver operating characteristic (ROC) curve
lot of the transformed TNF levels. All analyses were
onducted with SAS software (version 9.0; SAS Insti-
ute, Cary, NC).
ESULTS
NF Levels and Patient Characteristics
Two TNF categories were determined by cluster
nalysis with ranges of 0 to 5.5 pg/mL for the low
roup (n  58) and 7.5 to 1756 pg/mL for the high
roup (n  36). The clustered distribution of TNF
evels is shown in Figure 1. The characteristics of
atients in the entire group and in the 2 groups of
NF are shown in Tables 1 and 2, respectively.
MV Infection
CMV-Ag occurred in 44 (46.8%) patients, all
ithin 150 days after transplantation. The incidence
f positive CMV-Ag was signiﬁcantly lower in the
/R CMV transplants: only 2 (9.5%) of 21 pa-
ients of this type contracted CMV-Ag (log-rank
value comparing the 3 groups  .0019). The inci-
ence rates in the D/R (25/43; 58.1%) and
/R (17/30; 56.7%) groups were similar (log-rank
 .8097). Twenty-two (38%) patients in the low-
NF group developed CMV-Ag, and 22 (61%) pa-
ients in the high group developed CMV-Ag within
he ﬁrst 150 days after transplantation. By Kaplan-
eier analysis, the time to CMV-Ag onset was signif-
cantly associated with TNF levels (P  .0008; Figure
). High TNF levels were associated with a higher
igure 1. Patient groups by cluster analysis of posttransplantation
NF levels. Zero values are not shown on the log chart.
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TNF- and CMV Infection after Stem Cell Transplantation
Bncidence of CMV-Ag in related-donor transplanta-
ions (log-rank P  .0245), peripheral blood graft
ource transplantations (log-rank P .0018), and high
D3 count recipients (log-rank P  .0006).
By Cox regression, high TNF levels were inde-
endently associated with CMV-Ag (hazard ratio,
.57; 95% conﬁdence interval [CI], 1.37-4.82) when
djusting for possible confounding variables (Table 3).
cute GVHD was a signiﬁcant time-dependent covari-
te with an adjusted hazard for CMV-AG conversion of
.3 (95% CI, 1.22-4.33). Relative to transplantations in
hich both the donor and recipient were positive for
MV, transplantations with donor positive and recipient
igure 2. Kaplan-Meier plot of development of CMV-Ag and
able 2. Characteristics of Patient Groups by TNF Levels
Demographic Characteristic Low-TNF Group
atients
Sex match (%) 63.8
Recipient age, y (mean  SD) 46.1  12.
High disease risk (%)* 91.4
ransplant type
Myeloablative conditioning (%) 65.5
Peripheral blood stem cells (%) 58.6
Related donor transplant (%) 50.0
MV pretransplantation status
D (%) 63.8
R (%) 75.9
raft characteristics
High CD3 count (%)† 43.1
High CD34 count (%)‡ 74.1
o GVHD onset (%) 46.6
rade I GVHD (%) 3.5
rade II GVHD (%) 34.5
rade III GVHD (%) 13.8
rade IV GVHD (%) 1.7
High risk: acute myelogenous leukemia (AML) and acute lymphob
induction failure; acute leukemia from antecedent hematologic
not CP1); chronic lymphocytic leukemia; acute bilineage leukem
(MDS) not refractory anemia (RA) or ringed sideroblasts (RARS
AML CR1; CML CP1; MDS RA, RARS.
Median CD3 count: low-TNF group, 5  108/kg; high TNF, 5.1
Median CD34 count: low TNF, 1.8  106/kg; high TNF, 2.6 
Chi-square test for the association of GVHD grade and TNF grocorrelation with TNF levels.
B&MTegative were protective for CMV-Ag onset (adjusted
azard ratio [AHR], 0.11; 95% CI, 0.03-0.47).
omposite End Point
By Kaplan-Meier analysis, the time to CMV-Ag
nset or death was signiﬁcantly associated with TNF
evels (P  .0001; Figure 3). By Cox regression, the
igh TNF level was signiﬁcantly associated with the
omposite end point of CMV-Ag or death with an
HR of 2.42 (95% CI, 1.48-3.97). Also signiﬁcant in
he model were aGVHD onset (as a time-dependent
ovariate; AHR, 1.93; 95% CI, 1.13-3.31) and D/
 CMV pretransplantation status (AHR, 0.39; 95%
I, 0.19-0.80). Progression of disease was the single
ost common cause of death in both groups.
MV Disease
CMV disease occurred in 5 (8.6%) patients in the
ow-TNF group and 4 (11.1%) in the high-TNF
roup, but this was not statistically signiﬁcant in
aplan-Meier analysis (P  .2441). There was no
igniﬁcant association between donor/recipient pre-
ransplantation CMV combination and TNF group
2 P  .3134).
redictive Value of TNF Levels for the Composite
nd Point of CMV-Ag Onset or Death
We estimated the utility of using ﬁrst-week TNF
8) High-TNF Group (n  36) P Value
52.8 .290
47.0  12.7 .740
91.7 .961
63.9 .872
83.3 .013
94.4 <.001
75.0 .257
80.6 .595
63.9 .050
88.9 .083
41.7 .6068§
11.1
27.8
16.7
2.8
ukemia (ALL) other than ﬁrst complete remission (CR1), primary
r; chronic myelogenous leukemia not in ﬁrst chronic phase (CML
-Hodgkin lymphoma; Hodgkin disease; myelodysplastic syndrome
iple myeloma; eosinophilic leukemia (n  1). Low risk: ALL CR1;
/kg.
.(n  5
2
lastic le
disorde
ia; non
); mult
 108
106/kgytokine levels as a predictive diagnostic criterion for
701
C
d
a
o
i
i
m
h
o
(
g
1
e
(
b
o
p
u
0
v
t
s
D
r
m
b
e
a
o
a
t
t
c
w
t
i
T
s
t
m
s
t
a
s
[
s
i
o
l
t
a
p
T
3
a
C
a
b
d
f
i
q
t
l
m
S
h
cF
p
T
T
A
D
P
S
C
*
V. Reddy et al.
7MV-Ag and the composite end point of CMV-Ag or
eath in the 100 days after transplantation. For this
nalysis, patients had to have a minimum of 100 days
f posttransplantation follow-up (n  91). Therefore,
f a patient died before day 100, the patient was still
ncluded until the day of death and subsequently re-
oved from the analysis. Of the 36 patients in the
igh-TNF group, 22 (61%) developed CMV-Ag, as
pposed to 20 (36.4%) of 55 in the low-TNF group
2 P  .0206). Thirty patients (83%) in the high
roup experienced CMV-Ag or death within the ﬁrst
00 days after transplantation, whereas 30 (54.6%)
xperienced the combined end point in the low group
2 P  .0046). To further illustrate the relationship
etween the ﬁrst-week TNF count and the outcomes
f CMV-Ag or patient death, we produced an ROC
lot with the sensitivity and 1  speciﬁcity of partic-
lar TNF levels. The area under the ROC plot was
.622 (Figure 4), representing the overall predictive
alue or proportion of concordant observations be-
ween TNF levels and subsequent outcomes in the
ample.
ISCUSSION
TNF has been demonstrated to stimulate CMV
eactivation at a cellular level in a dose-dependent
anner, but the clinical signiﬁcance of this ﬁnding has
igure 3. Kaplan-Meier plot for outcome of CMV-Ag onset or
able 3. Multivariate Cox Model for Outcome of Time to CMV-Ag O
Variable (Reference Group) Le
NF level (low) High
cute GVHD onset Time-de
onor/recipient CMV pretransplantation status
(D/R)*
D/R
D/R
atient age Per yea
ex match (no) Yes
I indicates conﬁdence interval.
Excluding pretransplantation CMV D/R pairs.Patient death by TNF group level (excluding CMV DR pairs).
02een uncertain. Our study suggests that increased lev-
ls of TNF in the early posttransplantation period are
ssociated with a signiﬁcant risk for the development
f CMV infection that is independent of the onset of
GVHD. Murine and human studies have suggested
hat early TNF release due to conditioning-related
issue damage is associated with posttransplantation
omplications, particularly aGVHD [16,30]. Patients
ith aGVHD have an increased risk of CMV infec-
ion; however, a direct link between CMV and TNF
n SCT recipients was unknown. Increased plasma
NF levels and CMV-Ag have been documented in
olid-organ transplant recipients [23,31,32]. In renal
ransplant recipients, upregulation of CD4 T-cell
embrane-bound and soluble TNF responses was
een with CMV disease [33]. In addition, an associa-
ion of increased systemic TNF levels and CMV re-
ctivation has been found in nontransplant conditions
uch as sepsis, cirrhosis, and autoimmune disorders
22,31,34,35]. However, our study is the ﬁrst to de-
cribe the risk association between TNF and CMV
nfection in SCT recipients. In fact, our study dem-
nstrates that 76% of patients with high early TNF
evels develop CMV-Ag within the ﬁrst 100 days after
ransplantation (Figure 2). Even more striking was the
ssociation of increased TNF with the composite end
oint of CMV-Ag or death; 92% of patients with high
NF reached this end point within 150 days (Figure
). The multivariate Cox model conﬁrmed that this
ssociation was independent of other risk factors for
MV and was notably independent of the onset of
GVHD, thus indicating that there is a direct link
etween TNF levels and the risk for CMV disease and
eath.
CMV is a -herpesvirus that can be reactivated
rom latency in immunocompromised states, such as
n posttransplantation recipients or patients with ac-
uired immunodeﬁciency syndromes. Understanding
he immune mechanisms of CMV reactivation may
ead to newer therapies against CMV infections. The
echanisms by which TNF and CMV interact in
CT recipients require further investigation. TNF
as been shown to stimulate CMV reactivation at a
ellular level in a dose-dependent manner [22,23].
Hazard Estimate 95% CI P value
2.57 1.37-4.82 .003
nt 2.30 1.22-4.33 .010
0.11 0.03-0.47 .003
0.96 0.51-1.81 .894
1.02 1.00-1.05 .095
0.61 0.33-1.13 .116nset
vel
pende
rossible mechanisms for this association may be found
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TNF- and CMV Infection after Stem Cell Transplantation
Brom CMV pneumonitis animal models in transplan-
ation, in which human CMV infection induces TNF
elease from alveolar macrophages through a natural
iller cell and interferon –mediated immunopathol-
gy [36-38]. The upregulation of CMV infection by
NF is mediated via the TNF receptor 1 (p55) with a
ownstream signaling process that involves activation
f protein kinase C and nuclear factor-	B (NF	B).
he activated p65/p50 NF	B translocates into the
ucleus and binds to the 18–base pair repetitive se-
uence motifs with the human CMV immediate early
enhancer region [31,39]. On the basis of these mech-
nisms, the role of TNF leading to CMV reactivation
n our patients could be explained by the kidney trans-
lant CMV model, in which induction of immediate
arly 1 gene expression is the ﬁrst step in the reacti-
ation of CMV [40]. This occurs as a result of an
llogeneic response that induces the expression of
NF and subsequent activation of NF	B and activat-
ng protein 1 transcription factors [40]. This model
nd evidence of an association between CMV and
yeloid cellular differentiation [41-43] suggest that
he natural stimulus for CMV reactivation is an in-
ammatory response and that allogeneic transplanta-
ion mimics this inﬂammatory state.
Lack of CMV-speciﬁc cell-mediated immunity,
uch as lymphocyte function, is another important risk
actor for CMV reactivation [5,44]. Monocytes are an
mportant latent reservoir and may be susceptible to
he TNF effect. Soderberg-Naucler et al. [45] have
emonstrated that TNF and interferon  speciﬁcally
nduce differentiation of monocytes into CMV-per-
issive macrophages resistant to the antiviral effects
f these cytokines. However, in vitro studies by the
igure 4. ROC plot of ﬁrst-week TNF levels for the composite ou
n the ROC plot indicate original TNF levels in picograms per mame group supported a signiﬁcant CMV-permissive t
B&MTole for interferon  in monocytes rather than TNF
46]. Initial trials with blockade of TNF by using
nﬂiximab have yet to demonstrate a decrease in the
ncidence of CMV infection [24-26]. However, these
atients are at great risk for opportunistic infections
ecause of their immunosuppressed status from other
gents, including corticosteroids [24-26]. These pa-
ients also have severe GVHD, and GVHD is a known
isk factor for CMV infection. Therefore, reactivation
f CMV is likely a multifactorial complex phenome-
on in which TNF plays an important role but is not
lways tightly coupled.
Our study demonstrates that measurement of TNF
s early as the ﬁrst week after transplantation could be
sed as a clinical test to predict the development of
MV infection. Prior studies have suggested that cy-
okine levels may be intermittently increased during
MV infection [47,48]. A key difference between the
umar et al. [47] study and ours is that their study
ould not demonstrate an independent association be-
ween TNF and subsequent CMV infection. Their
esults demonstrate that TNF is increased around the
ime of development of CMV infection. This may be
ue to target organ damage during CMV infection.
onversely, our study found an association of early
NF levels with subsequent CMV activation. Our
tudy does not prove a pathogenic link between TNF
evels and CMV, but it legitimizes the hypothesis for
uch a link. Furthermore, earlier studies have evalu-
ted TNF levels at a later time point—several days to
eeks after engraftment. By this time point, many
atients are at risk for developing GVHD and require
orticosteroids or additional immunosuppression,
hich could alter TNF levels. Therefore, an advan-
of CMV-Ag or death within 100 days after transplantation. Valuestcomeage of our study is the measurement of TNF as part
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7f an early cytokine storm within days of transplanta-
ion, before the development of GVHD and addi-
ional immunosuppression and, more importantly, be-
ore the onset of CMV.
In our analysis, we excluded patients with a low risk
f developing CMV infection, ie, CMV-seronegative
ecipients of CMV-seronegative donors. The reason for
tudyingCMV-positive donors or patients and excluding
MV/ was to study the patient population at risk
or the ultimate outcome. As conﬁrmed by our data,
MV/ patients are at very low risk for CMV
eactivation. For that reason, when looking for a clin-
cally predictive test for CMV reactivation, the CMV-
ositive group is the appropriate study group.
In our multivariate analysis, there was a signiﬁ-
ant association between aGVHD and CMV-Ag (with
GVHD as a time-dependent covariate). Acute GVHD
as been a documented risk factor for CMV-Ag in pre-
ious studies [49,50]. Our study suggests that TNF is
ndependently associated with CMV-Ag, because we
orrected for aGVHD as a time-dependent covariate.
ot only was TNF associated with the onset of CMV-
g, but it also performed well as a predictive test. In fact,
linically it could be quite useful to have a test within 7
ays of transplantation to be able to predict CMV acti-
ation. Risk-stratifying patients before the development
f CMV-Ag could reduce the direct and indirect toxic-
ties of CMV infection and antiviral therapies. In fact,
MV prophylaxis instead of preemptive therapy
ight be justiﬁed in patients with early increases of
NF levels.
In summary, our results indicate for the ﬁrst time
hat high posttransplantation TNF levels are an inde-
endent risk factor for the development of CMV in-
ection independently of the onset of aGVHD. Be-
ause of the high predictive value of increased TNF
evels as early as 1 week after transplantation for CMV
nfection and death, this could be a useful marker in
dentifying high-risk patients and targeting preemp-
ive and preventative strategies.
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